PharmaJet Join Forces with Scancell to Develop and Commercialize Needle-free DNA Vaccine for Advanced Melanoma
Shots:
- PharmaJet and Scancell have signed a long-term license and supply agreement to develop and commercialize needle-free DNA vaccine for advanced melanoma
- The partnership will leverage PharmaJet Stratis Intramuscular (IM) Needle-free System to deliver Immunobody SCIB1/iSCIB1+ DNA vaccine for advanced melanoma
- As per the agreement, Scancell will utilize Stratis to develop and commercialize advanced melanoma DNA vaccine plus will handle its regulatory submissions. PharmaJet will get development & regulatory milestones plus net-sales based royalties
Ref: Businesswire | Image: PharmaJet & Scancell
Related News:- GI Innovation Join Forces with Merck to Evaluate GI-102 Plus Keytruda for Treating Various Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Bharat is a data whiz who collate and analyzes the data to generate valuable insights, contributing to both our monthly reports and the extraction of key information from press releases. Through his work, Bharat plays a crucial role in ensuring Pharmashots delivers the most relevant and up-to-date information to our readers.
